CBD has very low affinity for CB receptors. It functions being an antagonist or partial antagonist at endogenous cannabinoid receptors (both CB1 and CB2 receptor styles and also other G-protein-coupled receptors [GPCRs]) by inhibiting full binding of direct ligands, and could act generally at al